On June 9, the official website of the National Medical Products Administration (NMPA) showed that Henlius's serplulimab was approved for a new indication: in combination with oxaliplatin and tegafur/gimeracil/oteracil (S-1) for neoadjuvant treatment of patients with resectable gastric cancer with tumor PD-L1 expression combined positive score (CPS)≥5, followed by adjuvant monotherapy after surgery.
This approval was based on the positive results of the Phase III ASTRUM-006 study. The results showed that patients in the serplulimab plus chemotherapy group had significantly prolonged event-free survival (EFS) compared with those in the placebo plus chemotherapy group. Specifically, in the PD-L1 CPS≥5 population, the median EFS in the serplulimab plus chemotherapy group and the placebo plus chemotherapy group was not reached and 35.96 months, respectively (HR=0.73, P=0.015); in the PD-L1 CPS≥10 population, the median EFS in the serplulimab plus chemotherapy group and the placebo plus chemotherapy group was not reached and 42.0 months, respectively (HR=0.65, P=0.0082).